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Introduction: Osteopontin (OPN) is a phosphoglycoprotein with important roles in tissue homeostasis, wound
healing, immune regulation, and stress responses. It is expressed constitutively in the brain and upregulated during
neuroinflammatory responses; for example, after focal cerebral ischemia. To date, its effects on neural stem cells
(NSC) remain to be elucidated and are, accordingly, the subject of this study.
Method: Primary fetal rat NSC were cultured as homogenous monolayers and treated with different concentrations
of OPN. Fundamental properties of NSC were assessed following OPN exposure, including proliferative activity,
survival under oxidative stress, migration, and differentiation potential. To elucidate a putative action of OPN via the
CXC chemokine receptor type 4 (CXCR4), the latter was blocked with AMD3100. To investigate effects of OPN on
endogenous NSC in vivo, recombinant OPN was injected into the brain of healthy adult rats as well as rats
subjected to focal cerebral ischemia. Effects of OPN on NSC proliferation and neurogenesis in the subventricular
zone were studied immunohistochemically.
Results: OPN dose-dependently increased the number of NSC in vitro. As hypothesized, this effect was mediated
through CXCR4. The increase in NSC number was due to both enhanced cell proliferation and increased survival,
and was confirmed in vivo. Additionally, OPN dose-dependently stimulated the migration of NSC via CXCR4.
Moreover, in the presence of OPN, differentiation of NSC led to a significant increase in neurogenesis both in vitro
as well as in vivo after cerebral ischemia.
Conclusion: Data show positive effects of OPN on survival, proliferation, migration, and neuronal differentiation of
NSC. At least in part these effects were mediated via CXCR4. Results suggest that OPN is a promising substance for
the targeted activation of NSC in future experimental therapies for neurological disorders such as stroke.Introduction
Osteopontin (OPN) is an acidic phosphoglycoprotein
containing the adhesive motif arginine-glycine-aspartate
that interacts with various cell-surface integrins such as
αvβ1, αvβ3, and α5β1 (reviewed in [1]). In response to
injury and inflammation, OPN expression is induced in
a number of cells including macrophages, activated T
cells, osteoclasts, fibroblasts, epithelial cells, and vascular* Correspondence: adele.rueger@uk-koeln.de
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creativecommons.org/publicdomain/zero/1.0/smooth muscle cells [2–6]. Both a soluble isoform and
an intracellular isoform exist (reviewed in [1]). OPN
plays an important role in tissue homeostasis, wound
healing, immune regulation, and stress response [7, 8].
Intriguingly, under inflammatory conditions, it can
stimulate both pro- and anti-inflammatory processes,
depending on concomitant circumstances [7, 9–13]. In
the brain, OPN is expressed constitutively and is upregu-
lated with neuroinflammation (that is, in the subacute
stage of cerebral ischemia) 3–6 days after stroke [14–17].
In cerebral ischemia, OPN mediates neuroprotection via
two distinct mechanisms: a direct neuroprotective effect
on (cortical) neurons [18, 19], and an indirect neuropro-
tective effect of OPN mediated via the transcriptionalss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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tive reduction of secondary tissue damage [20].
Endogenous neural stem cells (NSC) residing in the
subventricular zone (SVZ) and in the hippocampal den-
tate gyrus of the adult mammalian brain are mobilized
following cerebral ischemia [21–23]. NSC mediate re-
generation and functional recovery after stroke by way
of neurogenesis and replacement of lost neurons, but
also via pleiotropic functions including neuroprotection,
reduction of neuroinflammation, revascularization, and
induction of plasticity (reviewed in [24]). Their ability to
migrate to a site of injury, to survive in the local envir-
onment, and potentially form new neurons, is crucial for
their function but is often impaired after stroke [25, 26],
contributing to the insufficient capacity of the brain for
self-repair and functional recovery. Thus, supporting the
proliferation, survival, and migration of endogenous
NSC seems to be a promising therapeutic approach in
stroke [22, 23, 27–31].
OPN is a potent chemoattractant, promoting the mi-
gration of cells of monocyte/macrophage lineage [32] as
well as of osteoclast precursors [33], mesenchymal stem
cells [34], and hematopoietic stem cells [35]. In the
brain, NSC are typically recruited to sites of brain injury
by the cytokine stromal cell-derived factor (SDF)-1α that
is expressed in the damaged tissue, acting on the CXC
chemokine receptor type 4 (CXCR4). CXCR4 is expressed
on various types of stem cells, including hematopoietic
stem cells [36] and NSC [37]. Zhang et al. demonstrated
that in cell lines from hepatocellular carcinoma, as an
analogue of SDF-1, OPN can also bind to CXCR4 and
promote cell migration [38].
To date, little is known about the effects of OPN on
NSC. For neural progenitor cells grown in neurosphere
cultures, OPN was suggested to increase proliferation
[39] and migration [40, 41] by yet unknown mecha-
nisms. We hypothesized that OPN promotes prolifera-
tion and migration of NSC through CXCR4 in vitro as
well as in vivo as a potential means of mobilizing and
attracting NSC to the brain after focal cerebral ischemia.
Moreover, we examined the effects of OPN on the differ-
entiation potential of NSC.
Material and methods
Cell culture
Primary NSC were cultured from fetal rat cortices at
embryonic day 13.5 as serum-free monolayers [22].
Briefly, cells were plated on dishes coated with poly-L-
ornithine and fibronectin, and expanded in Dulbeccos’s
modified Eagle’s/F12 medium (Life Technologies, Darm-
stadt, Germany) plus N2 supplement (Gibco, Karlsruhe,
Germany), penicillin/streptomycin, L-glutamine, and so-
dium pyruvate. As a mitogen, fibroblast growth factor
(FGF)2 was included at 10 ng/ml throughout theexperiments (Invitrogen, Karlsruhe, Germany). After first
passaging, homogenous NSC cultures were re-plated at
10,000 cells per cm2. Only NSC from the second until the
fifth passage were used for all experiments, in order to
utilize unaltered primary cells.
Immunocytochemistry
All immunocytochemical experiments were performed
in triplicate.
Characterization of NSC
Typical characteristics of NSC in culture were confirmed
immunocytochemically to verify homogeneity of the cul-
tures. Cells were fixed with 4 % paraformaldehyde (PFA)
and stained for: i) SRY (sex determining region Y) box 2
(SOX2) as a marker for undifferentiated (stem) cells
(mouse monoclonal, dilution 1:1000, cat-# MAB2018,
R&D Systems, Minneapolis, USA), and ii) their expression
of the cytokine receptor CXCR4 (polyclonal rabbit, dilution
1:250, cat-# 2042, Abcam, Bristol, UK). To detect a poten-
tial effect of OPN on the expression of CXCR4, NSC were
treated in the presence or absence of 3.125 μg/ml OPN for
24 h, then fixed in 4 % PFA and stained for CXCR4. For
visualization of SOX2 and CXCR4, fluorescein-labeled
anti-rabbit immunoglobulin (Ig)G were used (dilution
1:200, Invitrogen); all cells were additionally counterstained
with Hoechst 33342 (Life Technologies).
Cell number assessment
To assess the effects of OPN on NSC numbers, recom-
binant rat osteopontin (OPN; R&D Systems) with con-
centrations ranging from 1.25–12.5 μg/ml was added to
the cultures 1 h after re-plating. To assess the role of
CXCR4 in mediating any effects of OPN on cell num-
bers, we blocked this receptor with the CXCR4-
antagonist AMD3100 (Tocris Bioscience, Bristol, UK) at
a concentration of 10 μM in some wells directly after re-
plating, resulting in a pre-incubation time of NSC with
AMD3100 of 1 h before adding OPN. After 72 h, dead cells
were stained with propidium iodide (Life Technologies).
All cells, irrespective of viability, were counterstained with
Hoechst 33342 (Life Technologies) and representative
pictures were taken using an inverted fluorescence
phase-contrast microscope (Keyence BZ-9000E; Key-
ence, Neu-Isenburg, Germany). Ten images were taken
per well of a 24-well plate, and both Hoechst-stained
and propidium iodide-stained NSC were counted
manually. To calculate the ratio of living cells, the
number of propidium iodide-negative cells was divided
by the total (Hoechst-stained) number of NSC in each
sample, and mean values were established among
equally treated samples. Results were expressed as per-
cent of the control ± standard error of the mean
(SEM).
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To directly assess the effects of OPN on the proliferation
of NSC, cells were treated with OPN at a concentration
of 6.25 μg/ml for 72 h starting at re-plating. Cells were
fixed with 4 % PFA and were stained for the expression
of the proliferation marker Ki67 (rabbit polyclonal, dilu-
tion of 1:500, cat-# ab15580, Abcam). For visualization,
fluorescein-labeled anti-mouse IgG was used; all cells
were additionally counterstained with Hoechst 33342.
Representative pictures were taken using an inverted fluor-
escence phase-contrast microscope (Keyence BZ-9000E),
and Ki67-positive, proliferating NSC were counted manu-
ally. To calculate the ratio of proliferating cells, the number
of Ki67-positive cells was divided by the total cell number
in each sample, and mean values were established among
equally treated samples. Results were expressed as percent
of the control ± SEM.
Oxidative stress assay
To assess the effects of OPN on NSC under oxidative
stress, NSC were allowed to grow for 24 h after re-
plating, and were then treated with 300 nM 30 % H2O2
for 24 h (Merck, Darmstadt, Germany). OPN at 6.25
μg/ml was added to NSC cultures either with plating
(resulting in a pre-incubation time of 24 h before oxi-
dative stress, pre-treatment), or at the same time as the
addition of H2O2 (simultaneous treatment). After 24 h
under oxidative stress with H2O2, NSC were co-stained
with propidium iodide to label dead cells, and Hoechst
33342 to label all cells regardless of viability. Ten repre-
sentative images were taken per well of the 24-well
plate, and cells were counted manually. To calculate
the ratio of dead cells, the number of propidium
iodide-positive cells was divided by the total cell num-
ber in each sample, and mean values ± SEM were
established among equally treated samples.
Low-density plating
To further assess the effects of OPN in another cell
stress model, NSC were plated at very low density (266
cells/cm2) and grown in the presence or absence of OPN
at 6.25 μg/ml. After 8 days, NSC were co-stained with
propidium iodide to label dead cells, and Hoechst 33342
to label all cells regardless of viability. Five representative
images were taken per well of the 24-well plate, and cells
were counted manually. To calculate the ratio of living
cells, the number of propidium iodide-negative cells was
divided by the total cell number in each sample, and
mean values ± SEM were established among equally
treated samples.
NSC migration
NSC migration was analyzed via a trans-well migration
assay using a modified Boyden chamber (CytoSelect™24-Well Cell Migration Assay, 8 μM pore size; Cell Bio-
labs, Inc., San Diego, USA) according to the manufac-
turer’s protocol. Briefly, NSC were seeded in the inserted
upper chamber. To assess the role of CXCR4 in mediating
effects of OPN on migration, we blocked the receptor with
AMD3100 at a concentration of 10 μM in half of the wells
directly after plating for 1 h as pre-incubation before add-
ing OPN. After 1 h, either 10 μg/ml OPN, 10 % fetal calf
serum (FCS) as a positive control, or phosphate-buffered
saline as a negative control, were added to the lower
chambers of the modified Boyden chamber. After 48 h,
the non-migrating cells on the upper side of the inserts
were removed with a cotton tip. The migrating cells on
the lower side of the inserts were stained with Cell Stain
Solution for 10 minutes (Cell Biolabs, Inc.). Subsequently,
they were washed with phosphate-buffered saline and
allowed to air dry, before they were incubated with the
Extraction Solution (Cell Biolabs, Inc.). The optical
density of each sample was measured at 560 nm in a
plate reader (FLUOstar Omega; BMG LABTECH,
Ortenberg, Germany). Mean values ± SEM were estab-
lished among equally treated samples, and results were
expressed as percent of the control.
NSC differentiation
The differentiation potential of OPN-treated cells was in-
vestigated after withdrawal of the mitogen FGF2 during
the expansion phase. After 7 days, the culture medium
was replaced by Neurabasal Medium with GlutaMAX,
penicillin/streptomycin, L-glutamine, sodium selenite,
B27, NT3, and BDNF. After 7, 10, or 14 days of mitogen
withdrawal in the absence (control) or presence of 6.25
μg/ml OPN, NSC were fixed, then immunocytochemically
stained for markers for neuron specific beta-III tubulin
(anti-TuJ1; mouse monoclonal, dilution 1:100, R&D Sys-
tems), mature neurons (anti-MAP2; mouse monoclonal,
dilution 1:1000, Sigma-Aldrich, Munich, Germany), astro-
cytes (anti-GFAP; rabbit polyclonal, dilution 1:2500,
Abcam), oligodendrocytes (anti-CNPase; mouse monoclo-
nal, clone 11-5B, dilution 1:500, Millipore, Billerica, USA),
and undifferentiated stem cells (SOX2; mouse monoclo-
nal, dilution 1:1000, R&D Systems). Besides staining for
those single antigens, double-immunostaining was per-
formed for glial fibrillary acidic protein (GFAP) plus 2′,3′-
cyclic nucleotide 3′-phosphodiesterase (CNPase), in order
to differentiate between astrocytes and oligodendrocytes
in the same field of view. For visualization, fluorescein-
labeled anti-mouse IgG or anti-rabbit IgG were used; all
cells were additionally counterstained with Hoechst
33342. For quantification of the different fates of NSC,
cells were counted manually in representative fields of
view, taking into account those images displaying at least
one specifically stained cell. Mean values ± SEM were
established among equally treated samples.
Rabenstein et al. Stem Cell Research & Therapy  (2015) 6:99 Page 4 of 12Real-time quantitative PCR
All quantitative PCR experiments were performed in
quadruplicate.
RNA from cells was isolated using the RNeasy Mini
Kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s protocol. Total RNA concentration and purity
were evaluated photometrically. Total RNA was con-
verted to cDNA by reverse transcription with the Quan-
titect reverse transcription kit (Qiagen). The primer
used for Ki67 was obtained from Biolegio (Nijmegen,
The Netherlands). The sequences of the primers were: A)
forward, TCTTGGCACTCACAGTCCAG, and B) re-
verse, GCTGGAAGCAAGTGAAGTCC. The quantitative
PCR reaction was carried out using 10 ng total RNA in
20 μl reaction Quantitect Reagents (Qiagen) according
to the manufacturer’s recommendations. The samples
were amplified and quantified on a Rotorgene 2000
(Corbett, Sydney, Australia) using the following thermal
cycler conditions: activation, 95 °C, 10 minutes; cycling,
50 cycles; step1, 92 °C, 15 s; step 2, 52 °C, 15 s; step 3,
72 °C, 40 s. PCR product integrity was evaluated by
melting point analysis and agarose gel electrophoresis.
Each sample was normalized to RPL13a as reference
gene, and Ki67 mRNA levels were normalized to en-
dogenous RPL13a expression (ΔCT); normalized values
were then expressed as 2-ΔCt. Mean values ± SEM
were calculated for treated and untreated cells.
In vivo experiments
All animal procedures were in accordance with the
German Laws for Animal Protection and were approved
by the local animal care committee (Tierschutz-Ausschuss
FZ Juelich) and local governmental authorities (LANUV
NRW, AZ 84–02.04.2011.A169).
Photothrombosis
Adult male Fisher 344 rats weighing 200–300 g (n = 15)
were subjected to photothrombosis as a model of focal
cerebral ischemia. Animals were anesthetized by intra-
peritoneal injection of ketamine (75 mg/kg) and medeto-
midine (0.3 mg/kg), and placed in an atraumatic
stereotactical frame. The scalp was incised to expose the
skull surface. For illumination, a fiber-optic bundle with
a 1.5 mm aperture was placed onto the skull, using the
stereotactic coordinates 2 mm posterior and 3 mm lat-
eral from bregma. The skull was illuminated with a cold,
white light beam (150 W) for 20 minutes. During the
first 2 minutes of illumination, the dye rose bengal (1 %,
1 μl/g bodyweight) was injected into the tail vein. After-
wards, the scalp incision was sutured, and animals were
given an analgesic medication and allowed to recover
from anesthesia. Then they were put back into their
home cages, where they were given access to food and
water ad libitum.OPN treatment
To assess the effects of OPN on endogenous NSC,
in vivo animals subjected to photothrombotic stroke
and naïve adult male Fisher 344 rats weighing 200–300
g were treated with a single intracerebroventricular
(i.c.v.) injection of either 500 μg recombinant OPN
(R&D Systems) in 5 μl saline (stroke, n = 7; naïve, n = 5),
or 5 μl saline only as control (stroke, n = 8; naïve, n = 5),
using the stereotactic coordinates from bregma: antero-
posterior −0.9 mm, medio-lateral +1.4 mm, ventro-
dorsal +3.8 mm. In stroke rats, i.c.v. injection was
performed in the same session as induction of photo-
thrombosis. After surgery, animals were given an analgesic
medication, were allowed to recover from anesthesia and
were put back into their home cages, where they were
given access to food and water ad libitum.
To label dividing (stem) cells in vivo, the tracer bro-
modeoxyuridine (BrdU) was injected subcutaneously
every other day for 7 days at a dose of 50 mg/kg per in-
jection, starting on the day after i.c.v. injection of OPN
or placebo, respectively, leading to a cumulative dose of
200 mg/kg BrdU per animal.
Eight days after stroke and/or i.c.v. injection, rats were
sacrificed under deep anesthesia. Brains were extracted
and stored at −80 °C for further processing.
Immunohistochemistry
Coronal brain sections of 20 μm were cut throughout
the entire brain and fixed with 4 % PFA. To quantify the
number of endogenous NSC that had divided in the
week following OPN treatment, sections were stained
for BrdU incorporated into those cells (mouse monoclo-
nal, clone BU-33, dilution 1:200, cat-# B2531, Sigma-
Aldrich). For antigen-retrieval prior to BrdU-staining,
sections were microwave-heated in 0.01 M citrate buffer,
pH 6.0, for 5 minutes, followed by 2 N HCl at 37 °C for
30 minutes. To assess the effect of OPN on neurogen-
esis, sections were additionally stained for doublecortin
(DCX; goat polyclonal, dilution 1:800, cat-# sc-8066,
Santa Cruz Biotechnology, Dallas, USA). To assess the effect
of OPN on synaptogenesis, the sections were stained for
Synapsin-1 (rabbit polyclonal; dilution 1:1000, cat-#ab64581,
Abcam). For visualization of all primary antibodies, the
ABC Elite kit (Vector Laboratories, Burlingame, USA), with
diaminobenzidine (Sigma-Aldrich) as the final reaction
product, was used.
Representative images were taken throughout the SVZ
using a digital microscope (Keyence BZ-9000E). The
number of BrdU-positive cells in the SVZ was counted
manually, and mean values ± SEM were established
across animals of the same treatment group. To quantify
neuroblasts in the SVZ, the area covered by DCX-
positive cells was measured in μm2 using the software
BZ-II Analyzer (Keyence).
Rabenstein et al. Stem Cell Research & Therapy  (2015) 6:99 Page 5 of 12Statistical analysis
Descriptive statistics and Student’s t-tests were performed
with Microsoft Excel 2003 (Microsoft Corp., Redmond,
WA, USA). For comparison of multiple groups, one way
analysis of variance (ANOVA) was performed, following
Dunnett’s method for multiple comparisons. Statistical sig-
nificance was set at the less than 5 % level (p < 0.05).
Results
Undifferentiated NSC abundantly expressed CXCR4
Primary fetal rat NSC were grown in monolayer cultures
and characteristically expressed SOX2 as a marker for
undifferentiated cells (Fig. 1a). Immunocytochemical
staining revealed that the cytokine receptor CXCR4 was
expressed on nearly all primary NSC (Fig. 1b). This
abundant expression was unaffected by treatment with
6.25 μg OPN for 24 h (Fig. 1c).
OPN increased NSC numbers via CXCR4 signaling
To investigate the effect of OPN on NSC numbers, cells
were treated with OPN of various concentrations for 72Fig. 1 Undifferentiated NSC abundantly expressed CXCR4. a Primary fetal r
cells were counterstained with Hoechst (blue; scale bar represents 100 μm)
expressed abundantly on primary NSC; cells were counterstained with Hoe
for 24 h did not change the abundant expression of CXCR4 (red) on NSC (h. The number of viable NSC after this time was deter-
mined by co-staining cell nuclei with propidium iodide,
thereby identifying and excluding dead cells (Fig. 2a).
The number of viable NSC was significantly increased after
treatment with 6.25 μg/ml and 12.5 μg/ml OPN (p < 0.05;
Fig. 2a, b). Blockage of CXCR4 with 10 μM AMD 3100 1 h
prior to OPN-treatment completely blocked the positive
effect of OPN on NSC numbers (p < 0.05), while treatment
with AMD 3100 alone (without OPN) had no impact on
NSC numbers (Fig. 2a, b).
Since OPN at a concentration of 6.25 μg/ml led to the
highest increase in cell number, we used this concentra-
tion for all further experiments.
OPN increased both proliferation and survival of NSC
We further analyzed whether the positive effect of OPN
on NSC numbers was due to increased cell proliferation,
enhanced cell survival, or both.
To study the effects of OPN on NSC proliferation, we
analyzed the expression of the established proliferation
marker Ki67 both on the mRNA and the protein level.at NSC expressed SOX2 as a marker for undifferentiated cells (green);
. b Staining for CXCR4 (red) revealed that the cytokine receptor was
chst (blue; scale bar represents 50 μm). c Treatment with 6.25 μg OPN
blue: counterstaining with Hoechst; scale bar represents 50 μm)
Fig. 2 Osteopontin (OPN) increased neural stem cell (NSC) numbers via CXCR4 signaling. a Left panel: Untreated NSC (control) were stained with
Hoechst (blue), while dead NSC were additionally labeled with propidium iodide (red), allowing calculation of a ratio of viable NSC. Middle panel:
After treatment with 6.25 μg/ml OPN for 72 h, the number of viable NSC was increased. Right panel: Addition of AMD3100 to OPN-treated NSC
abrogated this effect (scale bar represents 100 μm). b OPN at concentrations of 6.25 and 12.5 μg/ml significantly increased the numbers of NSC
compared to control. Blocking CXCR4 with AMD 3100 for 1 h prior to OPN treatment completely abrogated the positive effect of OPN on NSC
numbers, while AMD 3100 alone had no effect (values displayed as means ± SEM; *p < 0.05)
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ment using real-time quantitative PCR. NSC treated
with OPN at 6.25 μg/ml for 72 h yielded significantly
more Ki67-mRNA than untreated NSC (p < 0.01; Fig. 3a).
Immunocytochemically, the percentage of Ki67-positive
cells was significantly increased after treatment with 6.25
μg/ml OPN for 72 h as compared to untreated cells, cor-
roborating quantitative PCR data at the protein level
(Fig. 3b).
To assess whether OPN exerted a similar effect on
NSC proliferation in vivo, adult male Fisher rats were
injected with a single dose of 500 μg OPN into the lateral
ventricle of the brain, and compared to sham-injected ani-
mals. For the following 8 days, BrdU was repetitively ad-
ministered systemically to label proliferating (stem) cells
in vivo. Treatment with OPN led to a significant increase
in BrdU-positive cells in the SVZ as the major NSC niche,
indicating that the effects of OPN on NSC proliferation
in vitro were reproducible in vivo (p < 0.01, Fig. 3c, d).
To assess a potential additional effect of OPN on the
survival of NSC, we exposed NSC cultures to severe oxi-
dative stress by adding 300 nM H2O2 for 24 h. Thisexposure led to an approximately threefold increase in
the percentage of dead NSC, as assessed by propidium
iodide staining (Fig. 3e). Pre-treatment of NSC with 6.25
μg/ml OPN 24 h prior to oxidative stress completely res-
cued the viability of NSC (p < 0.05; Fig. 3e). Even adding
OPN simultaneously with H2O2 prevented about half of
the cells from dying, confirming a positive effect of OPN
on NSC survival during cell stress (p < 0.01; Fig. 3e). To
confirm the positive effect of OPN on the survival of
NSC under stress conditions, we additionally plated
NSC at very low density and grew them in the presence or
absence of OPN for 8 days. Treatment with 6.25 μg/ml
OPN led to a significantly higher number of viable NSC
(p < 0.05; Fig. 3f). Of note, NSC adapted a slightly
branched morphology under stress conditions, which was
unaffected by OPN (Fig. 3g).
OPN promoted NSC migration via CXCR4 signaling
To assess the chemoattractant effect of OPN on NSC, a
modified Boyden chamber trans-well migration assay
was performed. NSC were treated with OPN at 5, 10 or
20 μg/ml for 48 h and compared to untreated cells as a
Fig. 3 Osteopontin (OPN) increased both survival and proliferation of neural stem cells (NSC). a NSC were treated with OPN at 6.25 μg/ml for 72
h. Quantitative PCR revealed that OPN treatment led to an increase in Ki67-mRNA, compared to untreated NSC (values displayed as means ±
SEM; **p < 0.01). b At the protein level, the percentage of Ki67-positive cells was significantly increased after treatment with 6.25 μg/ml OPN for
72 h (values displayed as means ± SEM; **p < 0.01). c Adult male rats injected with a single dose of 500 μg OPN intracerebroventricularly displayed a
significantly higher number of proliferating NSC in the SVZ as the major NSC niche, corroborating the effects of OPN on NSC proliferation in vivo
(values displayed as means ± SEM; **p < 0.01). d Representative images from the SVZ of rats treated with either placebo (left) or OPN (right; scale bar
represents 200 μm). e NSC cultures were exposed to oxidative stress by H2O2 (300 nM for 24 h), increasing cell death as assessed by propidium iodide
staining. Pre-treatment of NSC with 6.25 μg/ml OPN 24 h prior to oxidative stress completely rescued NSC from this toxicity, while simultaneously
addition of OPN and H2O2 prevented about half the cells from dying (values displayed as means ± SEM; *p < 0.05). f NSC cultures were plated at very
low density (266 cells/cm2). The numbers of living and dead cells were assessed by Hoechst and propidium iodide staining. Treatment with 6.25 μg/ml
OPN led to a significantly higher number of viable NSC after 8 days of incubation (values displayed as means ± SEM; *p < 0.05). g NSC plated
at very low density in the presence or absence of OPN at 6.25 μg/ml were assessed morphologically after 8 days. NSC adapted a slightly
branched morphology under the stress conditions of very low density plating, independent of OPN treatment (scale bars represent 50 μm).
BrdU bromodeoxyuridine
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attractant was used as a positive control. Upon addition
of OPN at a concentration of 10 μg/ml, a significantly
higher number of NSC migrated to the lower chamber
(p < 0.05, Fig. 4). This effect was completely abolished
by blocking CXCR4 with AMD 3100 (p < 0.05), while
the migration-promoting effect of FCS was unaffected
by AMD 3100, suggesting specific signaling of OPN via
CXCR4 (Fig. 4). AMD 3100 alone had no effect on NSC
migration (Fig. 4).
OPN promoted neurogenesis
To examine the effects of OPN on the differentiation
potential of NSC, cells were treated with 6.25 μg/mlOPN, while untreated cells served as control. During the
expansion phase, mitogen was withdrawn from NSC cul-
tures to induce differentiation, and cell fate was deter-
mined immunocytochemically after 7, 10, and 14 days
(Fig. 5a). Compared to untreated cells, the number of
neurons doubled after OPN treatment (p < 0.01,
Fig. 5b, d). In contrast, the other cell fates (i.e., astro-
cytes, oligodendrocytes) as well as the remaining un-
differentiated cells were slightly reduced, albeit to a
non-significant extent (Fig. 5b, c).
We further focused on the effect of OPN on neuro-
genesis at the late time points. From day 10 of differenti-
ation onward, an escalating formation of long neuronal
processes and network-like formations was observed.
Fig. 4 Osteopontin (OPN) promoted neural stem cell (NSC) migration via CXCR4 signaling. A modified Boyden chamber trans-well migration assay
was used to assess the effects of OPN on NSC migration, measuring the optical density of migrating cells, corresponding to their number. Growing
NSC in the presence of 10 μg/ml OPN for 48 h significantly increased their migration, while concentrations of 5 and 20 μg/ml did not have an effect.
The positive effect of OPN on NSC migration was completely blocked by treatment with AMD 3100, indicating that the effect was mediated through
CXCR4 receptor signaling. Fetal calf serum (FCS) served as positive control; its migration-promoting effect was unaffected by CXCR4 blockage. AMD
3100 alone did not affect NSC migration (values displayed as means ± SEM; *p < 0.05)
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ment (Fig. 5d, e). Furthermore, after 14 days of mitogen
withdrawal, several NSC had differentiated into mature
neurons, as indicated by immunolabeling with MAP2.
OPN-treated cells generated more neurons, which, in
turn, displayed denser neuronal networks (Fig. 5b, d, e).
To address the effect of OPN on neurogenesis in the
rat brain in vivo, DCX-positive young neuroblasts in the
SVZ were quantified 8 days after a single injection of
500 μg OPN into the lateral ventricle of the brain, while
placebo-injected animals served as control. While OPN-
treated animals displayed a slightly larger DCX-positive
area of the SVZ compared to the placebo-treated con-
trols, this effect was not statistically significant (Fig. 6a).
Under the hypothesis that OPN might promote neuro-
genesis to a larger extent in a model of stem cell-
mediated regeneration, we evaluated the effect of OPN
on neurogenesis in a rat model of focal cerebral ische-
mia. When rats subjected to photothrombotic stroke re-
ceived a single injection of 500 μg OPN into the lateral
ventricle of the brain, OPN-treated animals displayed
significantly more DCX-positive neuroblasts in the SVZ
compared to the placebo-treated controls (p < 0.01,
Fig. 6b, c).
Furthermore, we assessed the effect of OPN on synap-
togenesis in the naïve rat brain in vivo. However, after 8
days, the synapsin-1-positive cells in the SVZ of OPN-
treated naïve rats did not differ from control animals
(Additional file 1: Figure S1).
Discussion
We found OPN to enhance both survival as well as pro-
liferation of NSC. Data suggest that OPN increases the
numbers of NSC via the chemokine receptor CXCR4.
OPN has previously been shown to promote survival ofvarious cells including bone marrow cells [42], dendritic
cells [43], and cancer cells [44]. As a mechanism of ac-
tion, its binding to splice variants of the cell surface
glycoprotein CD44, activating the downstream PI3K
pathway, has been suggested [44, 45]. Our data extend
these findings by showing that beyond those types of
cells, the survival of NSC exposed to oxidative stress is
increased by OPN as well. This pro-survival effect of
OPN on NSC under oxidative stress might facilitate sur-
vival of these cells under ischemic conditions such as
stroke. Consistent with this assumption, OPN has been re-
ported to protect neurons from ischemic injury [18, 19].
Previous reports have discovered diverse effects of
OPN on cell proliferation. On the one hand, OPN was
shown to directly increase proliferation of various tumor
cells [45, 46]. Likewise, absence of OPN has been linked
to decreased cell proliferation of both tumor cells [47]
and erythroblasts [48]. On the other hand, OPN has
been shown to suppress proliferation of hematopoietic
stem cells through the induction of quiescence [35]. Re-
garding NSC, thus far non-conclusive effects of OPN on
proliferation have been reported: while some reports
failed to detect any effect of OPN on NSC proliferation
in vitro [41] or in vivo after experimental stroke [49],
others showed that NSC proliferation was reduced in
the absence of OPN in a mouse model of hypoxic brain
injury [50], or that OPN directly induced proliferation of
NSC grown as neurosphere cultures [39]. Kalluri and
Dempsey suggested that these seemingly contradictory
results could result from different experimental condi-
tions: they demonstrated that OPN increased NSC pro-
liferation in neurosphere cultures only in the presence of
FGF2 [39]. In our study, we found OPN increased the
proliferation in monolayer cultures of primary NSC
grown in the presence of FGF2, and additionally in the
Fig. 5 (See legend on next page.)
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Fig. 5 Osteopontin (OPN) promoted neurogenesis in vitro. a Neural stem cells (NSC) were allowed to differentiate for 7 days (d) after mitogen
withdrawal, yielding all three cell fates: neurons (above, green), astrocytes (middle, red), and oligodendrocytes (below, green; scale bars represents
50 μm). b Constant exposure of NSC cultures to OPN at 6.25 μg/ml during differentiation led to increased neurogenesis, while other cell fates
were slightly reduced, correspondently, albeit to a non-significant extent (values displayed as means ± SEM; **p < 0.01). c NSC were allowed to
differentiate for 7, 10, and 14 days after mitogen withdrawal in the presence or absence of OPN at 6.25 μg/ml; the number of undifferentiated
cells was subsequently assessed by staining against SRY (sex determining region Y) box 2 (SOX2). During that period, the number of undifferentiated
cells continuously declined, regardless of the presence of OPN (values displayed as means ± SEM). d Generation of TuJ1-positive neurons (green)
during differentiation was increased by OPN treatment (lower row) as compared to control (upper row) at days 7, 10, and 14 after mitogen withdrawal.
During that period, the axon length grew notably and neurons began to form networks; both observations were more pronounced in OPN-treated
cells. By day 14, mature MAP2+-positive neurons had formed (right column; scale bars represent 100 μm). e NSC were allowed to differentiate 10 and
14 days after mitogen withdrawal in the presence or absence of OPN at 6.25 μg/ml, and then their morphology was analyzed. Between day 10 and
day 14 after mitogen withdrawal, NSC differentiation further proceeded, the neurons formed long processes and network-like formations. This effect
was particularly pronounced in the OPN-treated cells (scale bars represent 100 μm)
Fig. 6 Osteopontin (OPN) promoted neurogenesis after stroke
in vivo. a After single i.c.v. injection of 500 μg OPN in adult,
unlesioned rats, OPN failed to significantly increase the area covered
by doublecortin (DCX)-positive young neuroblasts in the SVZ. b In
adults rats that underwent photothrombosis, a single i.c.v. injection
of 500 μg OPN significantly increased the area covered by DCX-positive
neuroblasts in the SVZ (values are displayed as means ± SEM,
**p < 0.01). c Representative, DCX-stained images from the SVZ
of rats subjected to cerebral ischemia, treated with either placebo
(left) or OPN (right). OPN treatment led to an increase of neuroblasts in
the SVZ (scale bar represents 100 μm)
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for the first time that these effects are mediated via the
cytokine receptor CXCR4 present on NSC.
OPN is a potent chemoattractant for various types of
stem cells such as mesenchymal [34] and hematopoietic
stem cells [35]. Yan et al. found that in the absence of
OPN less neuroblasts migrate towards an ischemic [40]
or hemorrhagic brain lesion [41]. In cultured neuro-
spheres, they found that blocking the integrin-β1 recep-
tor inhibited OPN-induced migration [40], in line with a
later report on OPN promoting the migration of mesen-
chymal stem cells via integrin-β1 [51]. In hepatocellular
carcinoma, on the other hand, OPN was shown to pro-
mote cell migration through the CXCR4 receptor [38].
We here demonstrate that migration of primary NSC
grown in homogenous monolayer cultures is also medi-
ated through CXCR4. The effects of both CXCR4 and
integrin-α4β1 on NSC migration are consistent with
their known support of the migration of hematopoietic
stem cells [52]. Relevant cross-talk between these two
pathways has also been described for neutrophils [53]
and tumor cells [54, 55], and seems to also occur in the
brain during autoimmune disorders [56].
To our knowledge, this is the first report describing a
direct pro-neurogenic effect of OPN on NSC. Yan et al.
have previously described that neutralizing OPN led to a
decreased number of neuroblasts in the ischemic stri-
atum, attributing this effect to a decreased migration of
neuroblasts from the SVZ towards the striatum [40].
Plantman et al. reported a positive effect of OPN on
neurite outgrowth of mature hippocampal neurons [57].
Our described direct positive effect of OPN on neuro-
genesis constitutes a novel aspect in stem cell-mediated
regeneration after stroke, since the inflammatory milieu
elicited after focal cerebral ischemia has primarily been
associated with a gliogenic fate of NSC [58, 59]. Up-
regulation of OPN in the inflammatory environment
after cerebral ischemia, as observed 3–6 days after stroke
[14–17], might thus counteract the glial differentiation
of NSC attracted towards the ischemic lesion, thereby
Rabenstein et al. Stem Cell Research & Therapy  (2015) 6:99 Page 11 of 12promoting regeneration and repair. Interestingly, we ob-
served a significant effect of OPN on neurogenesis
in vivo in animals that had undergone experimental
stroke. These findings further underline the concept of a
regulatory role of OPN under inflammatory conditions.
Conclusion
We here demonstrate positive effects of OPN on sur-
vival, proliferation, migration and neuronal differenti-
ation of NSC. Notably, OPN increased neurogenesis
both in vitro as well as in vivo after cerebral ischemia.
Since OPN is expressed in the subacute stages of focal
cerebral ischemia, its impact on NSC might physiologic-
ally serve to facilitate regeneration and recovery. Our
data strongly suggest that further studies investigating
the in vivo use of OPN for enhancing the brain’s cap-
acity for self-repair are warranted.
Additional file
Additional file 1: Figure S1: OPN did not influence synaptogenesis
in vivo. OPN failed to significantly increase the area covered by Synapsin-
1-positive cells in the SVZ after single i.c.v. injection of 500 μg OPN in
adult rats (scale bar represents 100 μm).
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